Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the general practice research database

United European Gastroenterology Journal

Volumn 2, Issue 6, 2014, Pages 505-512

  Card, Timothy R ^a   Siffledeen, Jesse ^b   Fleming, Kate M ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Case control study; Epidemiology; Inflammatory bowel diseases; Irritable bowel syndrome; Misdiagnosis

Indexed keywords

ALVERINE CITRATE; MEBEVERINE; PEPPERMINT OIL; SPASMOLYTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HUMAN; INFANT; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRIORITY JOURNAL; RISK FACTOR; ULCERATIVE COLITIS;

EID: 85006181403     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640614554217     Document Type: Article

References (23)

1. Sawczenko A, Sandhu BK, Logan RF, et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 2001; 357: 1093–1094.
2. Brown JS, Humphreys WG and Parks TG. Some clinical aspects of Crohn’s disease in Northern Ireland: An aid to earlier diagnosis? J R Coll Gen Pr 1988; 38: 549–551.
3. van Rheenen PF, Van de Vijver E and Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-analysis. BMJ 2010; 341: c3369.
4. Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14: 32–39.
5. Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: Prolonged symptoms before diagnosis – how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006; 4: 614–620.
6. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: A systematic review. Br J Clin Pharmacol 2010; 69: 4–14.
7. Lewis JD, Brensinger C, Bilker WB, et al. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2002; 11: 211–218.
8. Lewis JD, Bilker WB, Weinstein RB, et al. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005; 14: 443–451.
9. Garcıa Rodrıguez LA, Ruigomez A, Wallander MA, et al. Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. Scand J Gastroenterol 2000; 35: 306–311.
10. Hungin APS, Whorwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: An international survey of 40,000 subjects. Aliment Pharmacol Ther 2003; 17: 643–650.
11. Wilson S, Roberts L, Roalfe A, et al. Prevalence of irritable bowel syndrome: A community survey. Br J Gen Pract 2004; 54: 495–502.
12. Lewis JD, Aberra FN, Lichtenstein GR, et al. Seasonal variation in flares of inflammatory bowel disease. Gastroenterology 2004; 126: 665–673.
13. Minderhoud IM, Oldenburg B, Wismeijer JA, et al. IBSlike symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci 2004; 49: 469–474.
14. Isgar B, Harman M, Kaye MD, et al. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983; 24: 190–192.
15. Ansari R, Attari F, Razjouyan H, et al. Ulcerative colitis and irritable bowel syndrome: Relationships with quality of life. Eur J Gastroenterol Hepatol 2008; 20: 46–50.
16. Pimentel M, Chang M, Chow EJ, et al. Identification of a prodromal period in Crohn’s disease but not ulcerative colitis. Am J Gastroenterol 2000; 95: 3458–3462.
17. Gwee KA, Collins SM, Read NW, et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52: 523–526.
18. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778–1783.
19. Tornblom H, Lindberg G, Nyberg B, et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 1972–1979.
20. Keohane J, O’Mahony C, O’Mahony L, et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: A real association or reflection of occult inflammation? Am J Gastroenterol 2010; 105: 1788, 1789–1794; quiz 1795.
21. National Institute for Health and Care Excellence. NICE clinical guideline 61 – Irritable bowel syndrome in adults: Diagnosis and management of irritable bowel syndrome in primary care, http://www.nice.org.uk/CG61 (2008, accessed 30 January 2012).
22. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence- based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104(Suppl 1): S1–S35.
23. Whitehead S, Hutton J. Economic report: Value of calprotectin in screening out irritable bowel syndrome. CEP09041. Centre for Evidence-based Purchasing, NHS Purchasing and Supplies Agency, National Health Service, http://webarchive.nationalarchives.gov.uk/20100110130808/http://www.pasa.nhs.uk/pasa/Doc.aspx?Path=[MN][SP]/NHSprocurement/CEP/CEP09041.pdf (2010, accessed 13 July 2012).